查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球預測診斷市場
市場調查報告書
商品編碼
1176560

2023-2030 年全球預測診斷市場

Global Predictive Diagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預測診斷的全球市場預計在預測期內 (2023-2030) 將顯著增長。

預測性診斷使用定制數據和一套診斷工具來提供準確、實時的見解並識別潛在問題。 通過整合分子創新、基因組學應用和快速研發流程，預測診斷可以影響運營並帶來可衡量的進步。

市場動態

全球預測診斷市場受到技術進步、研發中越來越多地採用預測診斷、與生活方式相關的疾病日益流行以及健康意識不斷提高的推動。

預測診斷在醫療保健領域的優勢不斷增強，推動了市場增長

診斷領域的技術進步將在預測期內推動市場。 根據飛利浦 2020 年 6 月的一份報告，醫療保健領域的預測分析可以檢測重症監護病房和普通病房患者身體退化的早期跡象，識別家中的高危患者，並減少再次入院率。並有助於防止可避免的醫療停機時間設備。 預測診斷結合來自多個來源的數據，例如電子醫院病歷、跌倒檢測吊墜和醫療呼叫服務使用歷史，以識別未來 30 天內有救護車風險的老年人。我可以。 預測性診斷使醫療保健提供者能夠在跌倒和其他醫療並發症發生之前接觸到老年人，防止不必要的再入院，並減少運輸、急救和康復成本。

此外，市場參與者正在應用產品發布和合作等市場策略來擴展業務。 例如，2021 年 10 月，專注於體外診斷的法國跨國生物技術公司生物梅裡埃 (bioMerieux) 推出了其關於食品安全和食品質量的新主張——預測診斷。 同樣在 2022 年 9 月，QIAGEN 和 Neuron23 Inc.（一家專注於為遺傳定義的神經系統疾病和免疫疾病設計精準藥物的生物技術組織）宣布，Neuron23 的針對帕金森病的腦穿透富含亮氨酸重複序列。同意創建激□的伴隨診斷（ LRRK2) 抑製劑。 根據協議條款，QIAGEN 將設計和驗證一項臨床試驗分析，檢測 Neuron23 發現的生物標誌物的混合物，這些生物標誌物可預測帕金森病對 LRRK2 抑製劑的反應。 此外，此次合作將支持 Neuron23 候選藥物的臨床開發，這些候選藥物目前處於臨床前後期開發階段。 它還包括隨著臨床開發的進展開發其他伴隨診斷的選項。

缺乏預測診斷測試專業知識阻礙了市場增長

然而，生物標誌物識別慢性退行性疾病的不可靠性以及預測診斷測試專業知識的缺乏將在預測期內限制市場。

COVID-19 影響分析

COVID-19 的出現對全球預測診斷市場產生了積極影響。 根據 2020 年發表在 Advances in Biomarker Sciences and Technology 上的一篇文章，生物標誌物在大流行情況下尤為重要，因為它們可以加強新的創新藥物和生物製品的開發和批准，特別是在疫苗領域。據說是 生物標誌物很受關注，因為它們描述了特定疾病的可觀察特徵，並可用於根據其表型或基因型確定最佳治療方案。 特別是，急性呼吸窘迫綜合徵 (ARDS) 等呼吸系統疾病的生物標誌物與死亡率增加（IL-8、ICAM-1）和存活率提高（一氧化氮）有關。我知道。 這些生物標誌物在預測未來並發症和疾病嚴重程度方面具有關鍵作用，可能是 COVID-19 的有用預後指標。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 慢性病患病率上升
      • 各種癌症的增加
      • 需要及早發現各種遺傳疾病
    • 約束因素
      • 不可靠的生物標誌物
      • 缺乏專業知識
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 前驅型
  • 前驅型

第八章應用

  • 心血管疾病
  • 神經系統疾病
  • 遺傳病
  • 腫瘤學
  • 其他

第 9 章最終用戶

  • 診斷
  • 基因檢測機構/診所
  • 研究和學術機構

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 按類型劃分的基準

第12章公司簡介

  • Abbott Molecular
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Almac Group Ltd.
  • Ambry Genetics Corporation
  • BioGenex
  • Epistem Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genomic Health, Inc.
  • MDxHEALTH, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Prometheus Laboratories Inc.
  • Proteomics International Laboratories Ltd
  • QIAGEN N.V.

第13章 DataM

簡介目錄
Product Code: DMCD1123

Market Overview

The Global "Predictive Diagnostics Market" size was valued at US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

Predictive diagnostics employs customized data and a suite of diagnostic devices to deliver precise, real-time insights and identify potential problems. By integrating molecular innovations, genomics applications, and rapid R&D processes, Predictive diagnostics can assist deliver impactful and measurable advancements to operations.

Market Dynamics

The global predictive diagnostics market is driven by technological advancements, growing adoption of predictive diagnostics in research and development, rising lifestyle disease, and an increasingly health-conscious population.

Increasing benefits of predictive diagnostics in healthcare drives market growth

The technological advancements in diagnostics sectors drive the market in the forecast period. According to the Philips report, June 2020, predictive analytics in healthcare help detect early signs of patient degeneration in intensive care units and general wards, recognize at-risk patients in their residences to prevent hospital readmissions, and prevent avoidable downtime of medical equipment. Predictive diagnostics allows combining data from multiple sources - including hospital-based electronic medical records, fall detection pendants, and the historical use of medical alert services - to identify seniors at risk of emergency transport in the next 30 days. Predictive diagnostics allows healthcare providers to reach out to a senior person before a fall or another medical complication occurs, preventing unnecessary hospital readmissions and reducing transportation, acute care, and rehabilitation costs.

In addition, the market players are applying the market strategies such as product launches and collaboration to expand their business. For instance, in October 2021, bioMerieux - a French multinational biotechnology firm focusing on in-vitro diagnostics - launched predictive Diagnostics, the company's new offering in food safety and food quality. Also, in September 2022, QIAGEN and Neuron23 Inc., a biotechnology organization focused on designing precision medicines for genetically defined neurological and immunological diseases, agreed to create a companion diagnostic for Neuron23's brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson's disease. In this agreement, QIAGEN will design and validate a clinical trial assay that will detect a mixture of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to an LRRK2 inhibitor. Furthermore, this partnership will support the clinical development of Neuron23's drug candidate, which is presently in the late stages of preclinical development. Subject to further clinical development, the agreement also enfolds options for developing additional companion diagnostics.

The lack of expertise in predictive diagnostics testing will hamper the growth of the market

However, less reliability of biomarkers for identifying chronic degenerative diseases and lack of expertise in predictive diagnostics testing will restrain the market in the forecast period.

COVID-19 Impact Analysis

The appearance of COVID-19 positively impacted the global predictive diagnostics market. As per the article published in Advances in Biomarker Sciences and Technology in 2020, biomarkers are particularly important during a pandemic state since they can enhance the development and approval of new, innovative drugs and biological products, particularly in the field of vaccines. Biomarkers can be applied to describe observable characteristics of certain diseases and determine optimal treatments based on these phenotypes and genotypes; thence, they have received substantial attention. In particular, respiratory disease biomarkers, such as those associated with acute respiratory distress syndrome (ARDS), have been associated with increased mortality (IL-8, ICAM-1) and improved survival (nitric oxide). These biomarkers play a pivotal role in predicting future complications or disease severity and could be useful as an indicator for COVID-19 prognosis.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment accounts for the largest market share. Cancer is the foremost cause of death worldwide. The most familiar cancers are breast, colon, lung, rectum, and prostate. Cancer accounted for almost 10 million deaths in 2020 or nearly one in six.

As per the article published in Frontiers in Oncology in September 2022, predictive biomarkers in the context of progressive disease treated with chemotherapy are also included. A meta-analysis of clinicopathological features that predict necrosis/fibrosis in retroperitoneal residual masses of non-seminoma patients, including histopathological features in the orchiectomy specimen (absence of teratoma, presence of seminoma), as well as serum tumor markers (normal HCG and AFP, elevated LDH) and size of the mass (>50% change in size, smaller residual mass size). A

Also, identified features that predict the development of choriocarcinoma syndrome (a severe complication, challenging to treat and with considerable mortality) in poor-risk germ cell tumor patients, including metastatic lung involvement of more than half and ECOG PS around two. Rising cancer cases and demand for predictive diagnostics drives the market worldwide.

Geographical Analysis

North America region holds the largest market share of the global predictive diagnostics market

North America dominates the market for predictive diagnostics and is anticipated to show an equivalent trend over the forecast period. The market is driven by improved healthcare infrastructure, the increasing incidence of infectious disease, active regional key players, and easy availability of products in the region.

The market players are offering predictive diagnostics in the North American region. For instance, F. Hoffmann-La Roche Ltd provides predictive diagnostics solutions for oncology, cardiovascular disease, infectious disease, respiratory disease, autoimmune disease and more.

In addition, key players are adopting the market strategies such as acquisition and product launches. For instance, in December 2021, Roche acquired the TIB Molbiol Group. TIB Molbiol will continue to work as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will create their capabilities for the fast development of assays for emerging pathogens and potential health threats, such as infectious diseases.

Competitive Landscape

The predictive diagnostics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Abbott Molecular, Almac Group Ltd., Ambry Genetics Corporation, BioGenex, Epistem Ltd., F. Hoffmann-La Roche Ltd., Genomic Health, Inc., MDxHEALTH, Inc., Myriad Genetics, Inc., OPKO Health, Inc, Prometheus Laboratories Inc., Proteomics International Laboratories Ltd, and QIAGEN N.V., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the predictive diagnostics market globally.

For instance,

In September 2021, Janssen-a pharmaceutical subsidiary of Johnson & Johnson - introduced its nine-month startup accelerator - a program for the digital health startup space to gain innovative ideas on predictive diagnostics to discover precision treatments and therapies.

QIAGEN

Overview:

QIAGEN is a German organization founded in 1984 and headquartered in Hilden, Germany. It delivers the solutions for molecular testing and provides the answer from the building blocks of life- DNA, RNA, and protein to the customers to unblock the new insights.

Product Portfolio:

NextSeq 550Dx: This instrument is FDA-regulated and CE-in vitro diagnostic (IVD) marked, allowing clinical laboratories to design and execute a broad range of applications, from Next Generations sequencing solutions IVD assays using targeted panels to clinical research applications that include techniques from targeted panels to whole genomes.

The global predictive diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in prevalence of chronic diseases
      • 4.1.1.2. Increasing prevalence in various types of cancer
      • 4.1.1.3. Need for detection of various genetic disorders at the earliest stage
    • 4.1.2. Restraints:
      • 4.1.2.1. Less reliability of biomarkers
      • 4.1.2.2. Lack of expertise
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Presymptomatic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Predispositional

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurological Diseases
  • 8.4. Genetic Diseases
  • 8.5. Oncology
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Genetic Laboratories and Clinics
  • 9.4. Research and Academic Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Type Benchmarking

12. Company Profiles

  • 12.1. Abbott Molecular*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Almac Group Ltd.
  • 12.3. Ambry Genetics Corporation
  • 12.4. BioGenex
  • 12.5. Epistem Ltd.
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Genomic Health, Inc.
  • 12.8. MDxHEALTH, Inc.
  • 12.9. Myriad Genetics, Inc.
  • 12.10. OPKO Health, Inc.
  • 12.11. Prometheus Laboratories Inc.
  • 12.12. Proteomics International Laboratories Ltd
  • 12.13. QIAGEN N.V.

LIST NOT EXHAUSTIVE

13. Global Predictive Diagnostics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us